Characterization and Evaluation of a Novel Anticancer Drug, OSU-03012, As a Potential Therapeutic Agent for Hepatocellular Carcinoma
博士 === 國立臺灣大學 === 毒理學研究所 === 97 === Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. The incidence of HCC is estimated to range from ranging 500,000 to 1,000,000 new cases annually, causing 600,000 deaths worldwide per year. Surger...
Main Authors: | Ming Gao, 高明 |
---|---|
Other Authors: | Ann-Lii Cheng |
Format: | Others |
Language: | en_US |
Published: |
2009
|
Online Access: | http://ndltd.ncl.edu.tw/handle/38242575205064014360 |
Similar Items
-
DEVELOPMENT OF ANTICANCER AGENTS BY MODIFICATION OF A NOVEL IMMUNOSUPPRESSANT FTY720 AND PDK1 INHIBITOR OSU-03012
by: Ma, Yihui
Published: (2011) -
OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo
by: Ding L, et al.
Published: (2021-04-01) -
Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
by: Cyril Sobolewski, et al.
Published: (2021-07-01) -
The synthesis of novel anticancer agents with therapeutic potential
by: Ganeshapillai, Dharshini
Published: (2001) -
OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics
by: Kristien Van Belle, et al.
Published: (2018-01-01)